Timothy Boire, SBIR Recipient

The SBIR program has been and continues to be an extremely important, integral part of our business. We're a pre-revenue company in clinical trials, and have significant investor support due to the program. The program is also extremely critical for us now as we need the funds to continue to support clinical trial efforts, scale up manufacturing, and prepare for a commercial launch in the next 18 - 24 months.

This SBIR program at NIH specifically is really important to us. We have three applications with favorable scores that we are really relying on to determine how much more capital that we need from our current investors, and to scale up manufacturing. It is urgent that the SBIR program be reauthorized within the next two weeks to avoid causing undue harm to our company and many, many others.